Phase
Startup
Neola Medical
Neola Medical AB (publ) develops the first medical device for non-invasive continuous monitoring of lungs of preterm born babies, Neola® (Neonatal Lung Analyzer). Immediate detection of pulmonary complications provides the possibility of early treatment and improved health care. The patented technology is safe for the infant’s vulnerable skin and it is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 as a wholly owned subsidiary of Gasporox AB (publ) under the name GPX Medical AB. The company is listed on NASDAQ First North Growth Market (ticker: NEOLA).
Three qualities about Neola®:
- Faster detection of pulmonary complications preventing further major morbidities
- Decreased number of days in the expensive neonatal intensive care unit
- Decreased time for visual observation by nurses
Did you know?
Non-invasive cardiac pressure monitoring device
Accelerated drug development in oncology
Unique stem cell therapeutics
3D cell culture systems
Rapid Diagnostics for Multi-pathogen detection
Individualised information of the intestinal flora
Imaging solutions for life sciences
Novel probiotics for therapeutic effect
Treatments based on nature’s own defenses
Pest control solutions for bed bugs
Neonatal Lung Analyzer
Prebiotics for irritable bowel syndrome
Nanotechnology based infection control
Excellence in designing & executing drug discovery
Models for autoimmune & inflammatory conditions
Ultrasensitive cancer diagnostics & monitoring
Structural biology & drug discovery services
Male-Factor Infertility Diagnostics
Customized in vitro and in vivo services
Stroke detection device
Wound treatment gel
Regenerative medicine & cancer
